Skip to content
ADMETatlas
peptide evidence atlas
Home
About
Home

Browse

PeptidesProductsEvidenceContext signalsDescriptors

Developability

ProfileComparator

Resources

ManualExplanationsStatisticsDownloadLicenseAbout
  1. Home
  2. Peptides
  3. ATLPC0013052
Peptide·plain sequence-like

ATLPC0013052

ATLPC0013052

HAEGTFTSDVSSYLEGQAAKEFIAWLVNGTG

Compare in workbenchDownload releaseAPI JSON
  • Length
    31 aa
  • Monoisotopic mass
    3284.6 Da
  • Net charge @ pH 7.4
    -2.90
  • Isoelectric point
    4.15
  • GRAVY
    -0.100
On this page
  • 01 Sequence & molecular identity
  • 02 Physicochemical profile
  • 03 Metabolic & Proteolytic Stability
  • 04 Excretion / Persistence
  • 05 Evidence landscape
  • 06 Product context
  • 07 Identity & reference map
  • 08 Data access & reproducibility
Coveragecounts only · not riskATLPC0013052
  • Measurements
    6
  • Endpoints
    2
  • Domains
    2/5
  • Products
    —
  • 3 stability measurements
  • 3 clearance measurements
  • No immunogenicity context
  • 2 liability motifs
Jump to domain

Open the matching evidence section below

All evidence index · 6
Exposure / Absorption
No evidence
Distribution / Barrier
No evidence
Metabolic & Proteolytic Stability
3 measurements
Excretion / Persistence
3 measurements
Toxicity / Safety
No evidence
01

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

Sequence & peptidoform

·
Identity summaryCanonical sequence only
Identity status
Canonical sequence only
Residues
31
Peptidoform features
0
Documented molecular forms
1
Representations
2
Documented molecular forms1 form linked to this peptide identity
FormTopologyModificationsConnectionsRepresentationsMeasurements
ATLPF0014284———Notation only6
Residue view
Residue display
31 residues
H1A2E3G4T5F6T7S8D9V10S11S12Y13L14E15G16Q17A18A19K20E21F22I23A24W25L26V27N28G29T30G31
Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

No terminal modification, residue-level marker, disulfide, staple, coordination, or other topology signal is currently available.

Structure & chemistry

·
Chemical representationsequence / HELM only
Representation class

How the current release can interpret this identity chemically.

plain sequence-like
Parent-residue sequence

Residue string used for positional interpretation when available.

HAEGTFTSDVSSYLEGQAAKEFIAWLVNGTG
HELM

Polymer notation for modified peptide representation when available.

Not available
SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available
No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure referencesnone attached
3D structure not available

A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.

Covalent topology & modificationsnone
Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

02

Physicochemical profile

4 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

·
Core descriptors31 aa · pI 4.2 · GRAVY -0.10
Length
31 aa
Monoisotopic mass
3284.56 Da
Average mass
3286.56 Da
Net charge at pH 7.4
-2.90
Estimated pI
4.15
GRAVY
-0.100
KD-positive residues
35.5%
Aromatic residues
12.9%
Developability interpretation
Ionization context
pH 7.4 separated from pI
Hydrophobicity balance
Leans hydrophilic
Amphipathic moment (μH)
0.18
Computation boundary
Standard-sequence only
Charge & residue composition
pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2
2.94
pH 5
-1.58
pH 6
-2.19
pH 7.4
-2.95
pH 9
-3.80
pH 12
-5.93
Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Acidic (D,E)
4 · 12.9%
Basic (K,R,H)
2 · 6.5%
Polar uncharged (N,Q,S,T)
8 · 25.8%
Hydrophobic aliphatic (A,V,I,L,M)
9 · 29.0%
Aromatic (F,W,Y)
4 · 12.9%
Conformational / sulfur (G,P,C)
4 · 12.9%
Top residues
A412.9%G412.9%E39.7%S39.7%T39.7%L26.5%F26.5%V26.5%
Hydropathy & amphipathic windows
Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window
21-27
EFIAWLV
GRAVY 1.814
Most hydrophilic window
15-21
EGQAAKE
GRAVY -1.600
25 local hydropathy windows scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.
Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

12 aa window
17-28
QAAKEFIAWLVN
μH 1.71 · charge 0.0
12 aa window
18-29
AAKEFIAWLVNG
μH 1.43 · charge 0.0
12 aa window
19-30
AKEFIAWLVNGT
μH 1.42 · charge 0.0
12 aa window
16-27
GQAAKEFIAWLV
μH 1.40 · charge 0.0
15 aa window
17-31
QAAKEFIAWLVNGTG
μH 1.33 · charge 0.0
Sequence-liability cues
Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Asn deamidation motif
NG · pos 28
Asn followed by small/polar residues is a known sequence context to review for deamidation susceptibility.
Oxidation-sensitive residues
W · pos 25
Met, Trp, and Cys residues can merit formulation review for oxidation or covalent-state sensitivity.
Alpha-helix amphipathic projection
Helical wheel · Edmundson projection
μH = 0.18100°/residue · 31 aa
μH1: H (His) · Basic + · K-D -3.2H12: A (Ala) · Hydrophobic · K-D 1.8A3: E (Glu) · Acidic − · K-D -3.5E4: G (Gly) · Special · K-D -0.4G5: T (Thr) · Polar · K-D -0.7T56: F (Phe) · Aromatic · K-D 2.8F7: T (Thr) · Polar · K-D -0.7T8: S (Ser) · Polar · K-D -0.8S9: D (Asp) · Acidic − · K-D -3.5D10: V (Val) · Hydrophobic · K-D 4.2V1011: S (Ser) · Polar · K-D -0.8S12: S (Ser) · Polar · K-D -0.8S13: Y (Tyr) · Aromatic · K-D -1.3Y14: L (Leu) · Hydrophobic · K-D 3.8L15: E (Glu) · Acidic − · K-D -3.5E1516: G (Gly) · Special · K-D -0.4G17: Q (Gln) · Polar · K-D -3.5Q18: A (Ala) · Hydrophobic · K-D 1.8A19: A (Ala) · Hydrophobic · K-D 1.8A20: K (Lys) · Basic + · K-D -3.9K2021: E (Glu) · Acidic − · K-D -3.5E22: F (Phe) · Aromatic · K-D 2.8F23: I (Ile) · Hydrophobic · K-D 4.5I24: A (Ala) · Hydrophobic · K-D 1.8A25: W (Trp) · Aromatic · K-D -0.9W2526: L (Leu) · Hydrophobic · K-D 3.8L27: V (Val) · Hydrophobic · K-D 4.2V28: N (Asn) · Polar · K-D -3.5N29: G (Gly) · Special · K-D -0.4G30: T (Thr) · Polar · K-D -0.7T3031: G (Gly) · Special · K-D -0.4G31
Hydrophobic moment0.18
Mean K-D hydropathy-0.10
Approx. net charge-3
Projection angle100° / residue
The pale sector marks the direction of the hydrophobic face inferred from μH. This is a projection assumption, not a measured fold.
HydrophobicAromaticPolarBasic +Acidic −Specialhydrophobic faceμH arrow → hydrophobic face

The projection assumes an α-helix conformation; a long μH arrow indicates an amphipathic helix, common in antimicrobial peptides.Sequence > 30 aa — only termini and every fifth position are numbered because later turns share earlier wheel angles.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Sequence-derived

Computed from the standard parent-residue sequence; protein-origin metrics defined at any length.

Aliphatic index
69.35
Instability index
10.8

At or below 40 — predicted stable in vitro.

Boman index
0.89 kcal/mol
Molar extinction coefficient (280 nm)
6,990 M⁻¹·cm⁻¹

A280 (1 g/L) ≈ 2.13

Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.

03

Metabolic & Proteolytic Stability

3 records

How stable is the peptide in biological matrices or protease systems?

Evidence records
3
Complete canonical measurements and observations attached to this domain.
Endpoint scope
1
Formal ADMET endpoints represented for this peptide.
Matched-context analysis
3
Quantitative results that may be analysed only with scientifically compatible records.
Reported-result review
0
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeSerum/plasma stability
Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis
Quantitative results whose endpoint and context must still be matched before analysis.
3
Interpret as reported
Qualitative, narrative, or review-first findings preserved in source context.
0
Supporting context only
Reference, label, clinical, or supporting context for interpretation.
0
Review before analysis
Records whose present structure does not establish a safe analysis role.
0
Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

·
Serum/plasma stability3 records · 3 matched-context · 0 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

777.0 ± 10.2 Minutes

46620 seconds
Eligible when experimental context matches

RP-HPLC · mouse · Mouse serum

Result: Reported point value · Molecular form: ATLPF0014284 · Dose/window: 6 nmol · Mouse serum protease · In Vitro · Source: Primary reference linked

Reference
2

113.3 ± 11.8 Minutes

6798 seconds
Eligible when experimental context matches

RP-HPLC · mouse · Mouse serum

Result: Reported point value · Molecular form: ATLPF0014284 · Dose/window: 6 nmol · Mouse serum protease · In Vitro · Source: Primary reference linked

Reference
3

390.4 ± 13.5 Minutes

23424 seconds
Eligible when experimental context matches

RP-HPLC · mouse · Mouse serum

Result: Reported point value · Molecular form: ATLPF0014284 · Dose/window: 6 nmol · Mouse serum protease · In Vitro · Source: Primary reference linked

Reference
04

Excretion / Persistence

3 records

What evidence describes clearance or persistence?

Evidence records
3
Complete canonical measurements and observations attached to this domain.
Endpoint scope
1
Formal ADMET endpoints represented for this peptide.
Matched-context analysis
3
Quantitative results that may be analysed only with scientifically compatible records.
Reported-result review
0
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeHalf Life
Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis
Quantitative results whose endpoint and context must still be matched before analysis.
3
Interpret as reported
Qualitative, narrative, or review-first findings preserved in source context.
0
Supporting context only
Reference, label, clinical, or supporting context for interpretation.
0
Review before analysis
Records whose present structure does not establish a safe analysis role.
0
Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

·
Half Life3 records · 3 matched-context · 0 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

32.5 ± 1.4 Minutes

1950 seconds
Eligible when experimental context matches

RP-HPLC · 50 mM Tris–HCl (pH 7.4) buffer + 10 ng μL−1 DPPIV

Result: Reported point value · Molecular form: ATLPF0014284 · Dose/window: 0.3 nmol · DPP-IV · In Vitro · Source: Primary reference linked

Reference
2

245.3 ± 1.3 Minutes

14718 seconds
Eligible when experimental context matches

RP-HPLC · 50 mM Tris–HCl (pH 7.4) buffer + 10 ng μL−1 DPPIV

Result: Reported point value · Molecular form: ATLPF0014284 · Dose/window: 0.3 nmol · DPP-IV · In Vitro · Source: Primary reference linked

Reference
3

182.0 ± 0.1 Minutes

10920 seconds
Eligible when experimental context matches

RP-HPLC · 50 mM Tris–HCl (pH 7.4) buffer + 10 ng μL−1 DPPIV

Result: Reported point value · Molecular form: ATLPF0014284 · Dose/window: 0.3 nmol · DPP-IV · In Vitro · Source: Primary reference linked

Reference
05

Evidence landscape

6 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain
Eligible when context matches
Interpret as reported
Supporting context only
Review before analysis
Exposure / Absorption
0 evidence records
0
0
0
0
Distribution / Barrier
0 evidence records
0
0
0
0
Metabolic & Proteolytic Stability
3 evidence records
3
0
0
0
Excretion / Persistence
3 evidence records
3
0
0
0
Toxicity / Safety
0 evidence records
0
0
0
0
Endpoint distribution

Top evidence-bearing endpoint questions.

Half Life
3
Serum Plasma Stability
3
Assay context

Broad context buckets, useful before comparing values.

In vivo / route
3
Matrix / stability
3
Traceability

Reference-link availability for measurement-level audit.

Linked reference
6
Not linked
0
All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

#ADMET domainEndpointReported valueResult typeAnalysis useAssay / modelConditionReference
1
Metabolic & Proteolytic Stability
Stability
Serum Plasma Stability
777.0 ± 10.2 Minutes
46,620 seconds
Reported point valueEligible when experimental context matchesRP-HPLC · mouse · Mouse serumDose/window: 6 nmol · Protease: Mouse serum protease · In Vitro
Reference
Primary reference linked
2
Excretion / Persistence
Persistence
Half Life
32.5 ± 1.4 Minutes
1,950 seconds
Reported point valueEligible when experimental context matchesRP-HPLC · 50 mM Tris–HCl (pH 7.4) buffer + 10 ng μL−1 DPPIVDose/window: 0.3 nmol · Protease: DPP-IV · In Vitro
Reference
Primary reference linked
3
Metabolic & Proteolytic Stability
Stability
Serum Plasma Stability
113.3 ± 11.8 Minutes
6,798 seconds
Reported point valueEligible when experimental context matchesRP-HPLC · mouse · Mouse serumDose/window: 6 nmol · Protease: Mouse serum protease · In Vitro
Reference
Primary reference linked
4
Excretion / Persistence
Persistence
Half Life
245.3 ± 1.3 Minutes
14,718 seconds
Reported point valueEligible when experimental context matchesRP-HPLC · 50 mM Tris–HCl (pH 7.4) buffer + 10 ng μL−1 DPPIVDose/window: 0.3 nmol · Protease: DPP-IV · In Vitro
Reference
Primary reference linked
5
Metabolic & Proteolytic Stability
Stability
Serum Plasma Stability
390.4 ± 13.5 Minutes
23,424 seconds
Reported point valueEligible when experimental context matchesRP-HPLC · mouse · Mouse serumDose/window: 6 nmol · Protease: Mouse serum protease · In Vitro
Reference
Primary reference linked
6
Excretion / Persistence
Persistence
Half Life
182.0 ± 0.1 Minutes
10,920 seconds
Reported point valueEligible when experimental context matchesRP-HPLC · 50 mM Tris–HCl (pH 7.4) buffer + 10 ng μL−1 DPPIVDose/window: 0.3 nmol · Protease: DPP-IV · In Vitro
Reference
Primary reference linked
1–6 / 6
06

Product context

Product-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.

No product association in this release

This peptide is currently interpreted from sequence, structure, physicochemical, and ADMET evidence only.

Browse products
07

Identity & reference map

6 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

·
Summary1 reference group
Identity type
canonical sequence
Reported notation
0
Reference groups
1
Measurements
6
ATL peptide ID
ATLPC0013052
Identity concordance
Identity concordance
Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 6
Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 6
Different notation

Reported notation does not resolve to the current display sequence.

0 / 6
Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

6 / 6
Reported sequence notation

No source-specific sequence notation has been captured in the current identity references.

Current identity
HAEGTFTSDVSSYLEGQAAKEFIAWLVNGTG
Reported names
No distinct human-readable aliases are exposed.
Reference map1 reference group
Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

ReferenceSupportsReported identityRecords
Reference
Open
PersistenceStability
Half Life, Serum Plasma Stability
No reported alias
6 identity
6 evidence
08

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

·
Record scopePublic release
ATL peptide ID
ATLPC0013052
Identity type
canonical sequence
ADMET endpoints
2
Evidence records
6
Reference groups
1
Release view
Public release
Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements
Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint
GET /api/v1/peptides/ATLPC0013052
open
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0013052' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'
ADMETatlas
peptide evidence atlas

ADMETatlas is an open, curated atlas of ADMET evidence for therapeutic peptides — spanning developability, membrane permeability and blood–brain-barrier transport, immune-recognition context, and approved-product context. Every measurement stays linked to its original source, with stable identifiers and transparent curation, so results can be traced, cited, and reproduced.

Browse
PeptidesProductsEvidenceContext signalsDescriptors
Resource
DevelopabilityComparatorManualExplanationsStatisticsDownloadAbout
Stack
  • RDKit
  • Mol*
  • Python
  • FastAPI
  • PostgreSQL
  • Next.js
  • React
  • TypeScript
  • Tailwind CSS
  • Apache ECharts
© 2026 ADMETatlas, an academic peptide ADMET evidence atlas.